Regeneron announces ANGPTL3/Evinacumab publication in NEJM
Regeneron announced new data from genetics, preclinical and clinical studies published in the NEJM showed that people with inactivating mutations of the ANGPTL3 gene have significantly reduced risk of CAD and significantly lower levels of key blood lipids including triglycerides LDL-C. May 24, 2017